51. [Towards a better use of midazolam in end of life: A survey in a department of medical oncology].
- Author
-
Beneton A, Vallard A, Brosse C, Poenou G, Pacaut C, Magné N, and Morisson S
- Subjects
- Adult, Aged, Aged, 80 and over, Anxiety drug therapy, Anxiety etiology, Checklist, Clinical Decision-Making, Female, France, Guideline Adherence, Hospital Departments, Humans, Hypnotics and Sedatives administration & dosage, Inappropriate Prescribing prevention & control, Inappropriate Prescribing statistics & numerical data, Male, Midazolam administration & dosage, Middle Aged, Neoplasms psychology, Practice Guidelines as Topic, Practice Patterns, Physicians' statistics & numerical data, Respiratory Distress Syndrome drug therapy, Respiratory Distress Syndrome etiology, Retrospective Studies, Hypnotics and Sedatives therapeutic use, Medical Oncology methods, Midazolam therapeutic use, Neoplasms complications, Terminal Care methods
- Abstract
Introduction: At the end of life of cancer patients, sedation is sometimes needed, in order to palliate unbearable symptoms that other treatments fail to relieve. Midazolam is currently recommended for sedation and its prescription is guided by national guidelines. The aim of the present study was to evaluate the practices of midazolam prescription in a department of medical oncology and to compare the results with French national recommendations in order to improve the midazolam use in case of sedation., Methods: We conducted a retrospective survey studying midazolam prescriptions in patients who died between 2014 and 2015 in the medical oncology department. Compliance rates with recommendations were reviewed., Results: A total of 99 medical files were analyzed. Fifty-three patients received midazolam: 64.4% for refractory symptoms, 22% for anxiolyse, 10.2% for acute respiratory distress syndrome. When reported, the titration indications and modalities systematically conformed to guidelines. In case of sedation for refractory symptoms, adherence to guidelines was 76% regarding the family information, 63% regarding the patient information, 61% regarding the collegial nature of the initiation decision, 34% regarding the titration achievement and 5% regarding the pluridisciplinary nature of the initiation decision., Conclusion: Although limited justifications in midazolam prescriptions could have resulted in an overestimate of sedation and in an underestimate of titrations, current guideline are not enough applied in routine, especially regarding the necessity of a pluridisciplinary decision-making. A list of requirements before midazolam initiation is suggested, to increase the adherence to guidelines. Our results highlight the necessity of a better midazolam use in life-end sedations., (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF